Association between response to triptans and response to erenumab: real-life data

• Published in: Journal of headache and pain Vol. 22; no. 1; pp. 1 - 6
• Main Authors: Frattale, Ilaria, Caponnetto, Valeria, Casalena, Alfonsina, Assetta, Maurizio, Maddestra, Maurizio, Marzoli, Fabio, Affaitati, Giannapia, Giamberardino, Maria Adele, Viola, Stefano, Gabriele, Amleto, Pistoia, Francesca, Cerone, Davide, Marini, Carmine, Sacco, Simona, Ornello, Raffaele
• Format: Journal Article
• Language: English
• Published: Milan Springer Milan 06.01.2021; Springer Nature B.V; BMC
• Subjects: Antibodies, Monoclonal, Humanized; Calcitonin; Calcitonin gene-related peptide; Calcitonin Gene-Related Peptide Receptor Antagonists; CGRP; Drug therapy; Erenumab; Headache; Humans; Internal Medicine; Medicine; Medicine & Public Health; Migraine; Migraine Disorders - drug therapy; Migraine treatment; Monoclonal antibodies; Neurology; Pain management; Pain Medicine; Pathophysiology; Pharmacokinetics; Short Report; Triptans; Tryptamines; Triptans; Erenumab; CGRP; Migraine treatment
• ISSN: 1129-2369; 1129-2377; 1129-2377
• DOI: 10.1186/s10194-020-01213-3

Background Triptans and erenumab are both migraine-specific agents acting on the calcitonin gene-related peptide pathway. Therefore, response to triptans might be associated with response to erenumab. Main body In our study, consecutive patients referring to the Headache Centers of the Abruzzo region from January 2019 to March 2020 and treated with erenumab were interviewed about past use and efficacy of triptans. Triptan users were classified as ‘triptan responders’ if they were headache-free 2 h after treating ≥3 migraine attacks with ≥1 triptan. We considered patients as ‘erenumab responders’, if they had a ≥ 50% mean reduction in monthly migraine days between the 4th and the 6th month from treatment start compared with baseline. Of 91 triptan users, 73 (80.2%) were triptan responders and 58 (63.7%) were erenumab responders. The odds ratio of being erenumab responder was 3.64 (95% CI, 1.25–10.64) for triptan users as compared to non-users. ( P  = 0.014). Besides, starting erenumab improved triptan response in both erenumab responders and non-responders. Conclusions Our data of an association between response to triptans and response to erenumab can be useful for patient advice and to improve the understanding of migraine pathophysiology and treatment.